SKIN The Journal of Cutaneous Medicine

Safety of Tazarotene 0.045% Lotion and Hyperpigmentation Improvements in Black Participants With Moderate-to-Severe Acne

Fran E Cook-Bolden, MD, Linda Stein Gold, MD, Hilary Baldwin, MD, Valerie Callender, MD, Andrew F Alexis, MD, MPH, Neal Bhatia, MD, Joshua A Zeichner, MD, Emil A Tanghetti, MD, Eric Guenin, PharmD, PhD, MPH

Page s221

Poster PDF

Efficacy and Safety of a Novel Tazarotene 0.045% Lotion in Females and Males with Moderate-to-Severe Acne

H Baldwin, L Green, L Kircik, E Guenin

Page S15

Poster PDF

Real World Patient Perceptions of the use of Tazarotene 0.1% Foam in the Treatment of Acne Vulgaris

James Q Del Rosso, Corey L Hartman, Caitlin Lewis, Rhonda Schreiber

Page S4

Poster PDF

Comparison of a Novel Tazarotene 0.045% Lotion to Tazarotene 0.1% Cream: Patient-Reported Outcomes from a Phase 2 Clinical Trial

Zoe Draelos, Fran Cook-Bolden, Lawrence Green, Eric Guenin, Gina Martin, Radhakrishnan Pillai

Page S9

Poster PDF

Comparison of a Novel Tazarotene 0.045% Lotion to Tazarotene 0.1% Cream: Patient-Reported Outcomes from a Phase 2 Clinical Trial

Z Draelos, F Cook-Bolden, L Green, E Guenin, G Martin, R Pillai

Page S19

Poster PDF

Efficacy and Tolerability of Tazarotene Foam 0.1% Across Age, Gender, and Race: An Integrated Review of Two Phase III Trials

Rhonda Schreiber, Kaytiana Crane, Juhin Patel

Page s50

Poster PDF

Acne Keloidalis Nuchae Successfully Treated with Halobetasol 0.01% and Tazarotene 0.045% Lotion

Olga Marushchak, Kathryn Jayne Tan, Maria Rosa Noliza Encarnacion, Loren Clark, Alexandra Golant

Page 311-314

PDF

Patient Assessment of Foam Attributes from the Tazarotene Foam, 0.1%, Phase III Trials and Potential Impact on Patient Compliance

Rhonda Schreiber, Caitlin Lewis, Kaytiana Crane

Page S57

Poster PDF

Tazarotene 0.045% Lotion for Acne: Formulation, Application Characteristics, and Clinical Efficacy and Safety

Zoe Draelos, Emil Tanghetti, Linda Stein Gold, Hilary Baldwin, Leon Kircik, Eric Guenin

Page s69

Poster PDF

Improvements in Acne and Skin Oiliness with Tazarotene 0.045% Lotion in Acne Patients with Oily Skin

Emil Tanghetti, Michael Gold, Neil Sadick, Fran Cook-Bolden, Leon Kircik, Linda Stein Gold, Stephen Tyring, James Del Rosso, Eric Guenin

Page s71

Poster PDF

Tazarotene 0.045% Lotion for Truncal Acne: Efficacy, Safety, and Spreadability

Leon Kircik, Zoe Draelos, Eric Guenin

Page s43

Poster PDF

Tazarotene 0.045% Lotion for Truncal Acne: Efficacy, Tolerability, and Spreadability

Leon Kircik, Zoe D Draelos, Eric Guenin

Page s84

Poster PDF

Efficacy and Safety of Tazarotene 0.045% Lotion in White Adults with Moderate-to-Severe Acne

James Del Rosso, Linda Stein Gold, Stephen Tyring, William Philip Werschler, Fran Cook-Bolden, George Han, Neal Bhatia, Eric Guenin

Page s70

Poster PDF

Efficacy and Safety of a Novel Tazarotene 0.045% Lotion in Females and Males With Moderate-to-Severe Acne

Hilary E Baldwin, Lawrence Green, Leon Kircik, Ashlie M Caronia, Eric Guenin

Page s60

Poster PDF

Comparison of Cutaneous Irritation With Repeated Application of Tazarotene 0.045% Lotion, Adapalene 0.3% Gel, and Trifarotene 0.005% Cream

Zoe D. Draelos, MD, Patricia Farris, MD, Hilary Baldwin, MD, Emil A Tanghetti, MD

Page s158

Poster PDF

Tazarotene 0.045% Lotion for Females With Acne: Analysis of Two Different Adult Age Groups

Neil Sadick, Fran Cook-Bolden, Kenneth Beer, Zoe Draelos, Leon Kircik, Emil Tanghetti, Eric Guenin

Page s18

Poster PDF

Treating Acne in Obese and Morbidly Obese Patients With Tazarotene 0.045% Lotion: Post Hoc Analysis of Pooled Phase 3 Data

Jonette Keri, Leon Kircik, Lawrence Green, Glynis Ablon, William Werschler, Emil Tanghetti, Zoe Draelos, Eric Guenin

Page s12

Poster PDF

Efficacy and Safety of Tazarotene 0.045% Lotion in Female Patients with Moderate-to-Severe Acne: Post Hoc Analysis by Age

Linda Stein Gold, Hilary Baldwin, Fran Cook-Bolden, Lawrence Green, Glynis Ablon, Neil Sadick, Jonathan Weiss, Eric Guenin

Page s23

Poster PDF

Novel Polymeric Tazarotene 0.045% Lotion for Moderate-to-Severe Acne: Pooled Phase 3 Analysis by Race

Fran E Cook-Bolden, Neal Bhatia, Jonathan S Weiss, Neil Sadick, Stephen K Tyring, Eric Guenin, Anya Loncaric, Susan Harris

Page s88

Poster PDF

Real World Patient Perceptions of the use of Tazarotene 0.1% Foam in the Treatment of Acne Vulgaris

James Q Del Rosso, Corey L Hartman, Caitlin Lewis, Rhonda Schreiber

Page s58

Poster PDF

Search

Search Results